EUVIMEDEUVIMED entdecken
Validierungsstudie

Training and validation of a novel 14‐gene expression signature associated with prostate cancer metastasis and postoperative recurrence

Eva F Jensby, Søren Klingenberg, Jacob Fredsøe, Kia E Fonfara, Benedicte P Ulhøi, Michael Borre, Mads R Jochumsen, Kirsten Bouchelouche, Karina D Sørensen iD

International Journal of Cancer · 2026

DOI: 10.1002/ijc.70247 ↗

Kurz gefasst

Validierungsstudie in der Zeitschrift International Journal of Cancer, 2026. Verfasst von Eva F Jensby und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Molecular Medicine, Aarhus University Hospital (AUH), Aarhus, Denmark. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Neoplasm Recurrence, Local, Biomarkers, Tumor, Transcriptome. Die Arbeit nennt 49 Literaturangaben. Gefördert von: Independent Research Fund Denmark, Novo Nordisk Foundation, Danish Cancer Society.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Novel biomarkers are needed to improve prostate cancer risk stratification at diagnosis, as current clinical practice is suboptimal. Here, using a training cohort of 107 newly diagnosed prostate cancer patients, primary staged by 68 Gallium prostate‐specific membrane antigen (PSMA) Positron Emission Tomography‐Computed Tomography (PET/CT) imaging (41 localized and 66 metastatic; Cohort 1), we aimed to train a gene expression signature associated with metastasis, a key hallmark of aggressiveness. By mRNA sequencing of primary tumor tissue samples from 107 patients in Cohort 1 and use of Least Absolute Shrinkage and Selection Operator regression, we trained a novel 14‐gene model (CaP14) that distinguished localized and metastatic prostate cancer (MPC). Associations between CaP14 and disease outcomes were tested in three independent cohorts, including 17 MPC and 127 radical prostatectomy (RP) patients (Cohort 2), 473 RP patients (Cohort 3), and 174 RP patients (Cohort 4), respectively. Diagnostic/prognostic performance of CaP14 was assessed by receiver operating characteristics, Kaplan–Meier, uni/multivariate Cox regression, and biochemical recurrence (BCR)‐free and prostate cancer‐specific survival analyses. A high CaP14 score was associated with metastasis and poor prostate cancer‐specific survival in Cohorts 1 and 2, and with early BCR in RP Cohorts 2, 3, and 4 independently of routine clinical variables. This is the first study to develop a gene signature capable of predicting metastasis at initial diagnosis, trained using a cohort of patients whose metastatic spread was evaluated using 68 Ga‐PSMA PET/CT scans. CaP14 has the potential to guide better and more personalized treatment decisions for newly diagnosed prostate cancer in the future.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostatic NeoplasmsNeoplasm Recurrence, LocalBiomarkers, TumorTranscriptomeHumansMaleAgedMiddle AgedPositron Emission Tomography Computed TomographyProstatectomyPrognosisNeoplasm MetastasisGene Expression ProfilingGene Expression Regulation, Neoplastic

Stichwörter der Autor:innen

68Ga‐PSMA PET/CTbiomarkerprognosisprostate cancertumor RNA sequencing

Substanzen

Biomarkers, Tumor

Autor:innen und Institutionen

  • Department of Molecular Medicine, Aarhus University Hospital (AUH), Aarhus, Denmark.
  • Department of Clinical Medicine, Aarhus University, Aarhus, Denmark.
  • Department of Nuclear Medicine and PET-Centre, Aarhus University Hospital (AUH), Aarhus, Denmark.
  • Department of Pathology, Aarhus University Hospital (AUH), Aarhus, Denmark.
  • Department of Urology, Aarhus University Hospital (AUH), Aarhus, Denmark.

ORCID-Profile: Karina D Sørensen

Förderung

  • Independent Research Fund Denmark
  • Novo Nordisk Foundation
  • Danish Cancer Society
  • Danmarks Frie Forskningsfond
  • Novo Nordisk Fonden
  • Kræftens Bekæmpelse

Zitieren

APA

Jensby, E. F., Klingenberg, S., Fredsøe, J., Fonfara, K. E., Ulhøi, B. P., Borre, M., Jochumsen, M. R., Bouchelouche, K., & Sørensen, K. D. (2026). Training and validation of a novel 14‐gene expression signature associated with prostate cancer metastasis and postoperative recurrence. International Journal of Cancer. https://doi.org/10.1002/ijc.70247

Vancouver

Jensby EF, Klingenberg S, Fredsøe J, Fonfara KE, Ulhøi BP, Borre M, et al. Training and validation of a novel 14‐gene expression signature associated with prostate cancer metastasis and postoperative recurrence. International Journal of Cancer. 2026. doi:10.1002/ijc.70247

BibTeX
@article{Jensby2026,
  author = {Jensby, Eva F and Klingenberg, Søren and Fredsøe, Jacob and Fonfara, Kia E and Ulhøi, Benedicte P and Borre, Michael and Jochumsen, Mads R and Bouchelouche, Kirsten and Sørensen, Karina D},
  title = {Training and validation of a novel 14‐gene expression signature associated with prostate cancer metastasis and postoperative recurrence},
  journal = {International Journal of Cancer},
  year = {2026},
  doi = {10.1002/ijc.70247}
}
Kostenlos starten →